» Articles » PMID: 35224540

A Review Into the Effects of Pamidronic Acid and Zoledronic Acid on the Oral Mucosa in Medication-Related Osteonecrosis of the Jaw

Overview
Date 2022 Feb 28
PMID 35224540
Authors
Affiliations
Soon will be listed here.
Abstract

Medication-related osteonecrosis of the jaw (MRONJ) is a growing problem without an effective treatment, presenting as necrotic bone sections exposed via lesions in the overlying soft tissue. There is currently a lack of clarity on how the factors involved in MRONJ development and progression contribute to disease prognosis and outcomes. Bisphosphonates (BPs), the most common cause of MRONJ, affect bone remodeling, angiogenesis, infection, inflammation and soft tissue toxicity, all of which contribute to MRONJ development. This article reviews the cellular mechanisms through which BPs contribute to MRONJ pathology, with a focus on the effects on cells of the oral mucosa. BPs have been shown to reduce cell viability, reduce proliferation, and increase apoptosis in oral keratinocytes and fibroblasts. BPs have also been demonstrated to reduce epithelial thickness and prevent epithelial formation in three-dimensional tissue engineered models of the oral mucosa. This combination of factors demonstrates how BPs lead to the reduced wound healing seen in MRONJ and begins to uncover the mechanisms through which these effects occur. The evidence presented here supports identification of targets which can be used to develop novel treatment strategies to promote soft tissue wound healing and restore mucosal coverage of exposed bone in MRONJ.

Citing Articles

Determinants of outcome in cancer patients with medication-related osteonecrosis of the jaw: A 19-year retrospective study.

Ward J, Singh A, White C, Riedel E, Lewis R, Yom S Oral Oncol Rep. 2024; 10.

PMID: 38957376 PMC: 11218890. DOI: 10.1016/j.oor.2024.100488.


Antiresorptive agents enhance ossification of free flap reconstructions of the mandible: a radiological retrospective cohort study.

Gottsauner M, Meier J, Eichberger J, Eckmuller S, Schuderer J, Fiedler M Front Oncol. 2024; 14:1401165.

PMID: 38933444 PMC: 11200174. DOI: 10.3389/fonc.2024.1401165.


Medication-related osteonecrosis of the jaw: Case series and literature review.

Kimathi D, Butt F, Guthua S, Waweru W Clin Case Rep. 2024; 12(4):e8788.

PMID: 38645603 PMC: 11031743. DOI: 10.1002/ccr3.8788.


Rodents as an animal model for studying tooth extraction-related medication-related osteonecrosis of the jaw: assessment of outcomes.

Hadad H, Matheus H, Pai S, Souza F, Guastaldi F Arch Oral Biol. 2023; 159():105875.

PMID: 38160519 PMC: 11729500. DOI: 10.1016/j.archoralbio.2023.105875.


Effect of Geranylgeraniol (GGOH) on Bisphosphonate-Induced Cytotoxicity of Oral Mucosa Cells.

Rattanawonsakul K, Bullock G, Bolt R, Claeyssens F, Atkins S, Hearnden V Front Oral Health. 2022; 3:892615.

PMID: 35795156 PMC: 9251184. DOI: 10.3389/froh.2022.892615.

References
1.
Paulo S, Abrantes A, Laranjo M, Carvalho L, Serra A, Botelho M . Bisphosphonate-related osteonecrosis of the jaw: specificities. Oncol Rev. 2015; 8(2):254. PMC: 4419650. DOI: 10.4081/oncol.2014.254. View

2.
Coleman R . Bisphosphonates and breast cancer - From cautious palliation to saving lives. Bone. 2020; 140:115570. DOI: 10.1016/j.bone.2020.115570. View

3.
Agis H, Blei J, Watzek G, Gruber R . Is zoledronate toxic to human periodontal fibroblasts?. J Dent Res. 2009; 89(1):40-5. DOI: 10.1177/0022034509354298. View

4.
Matsunaga S, Iguchi K, Usui S, Hirano K . Incadronate induces cell detachment and apoptosis in prostatic PC-3 cells. Anticancer Res. 2007; 27(2):927-32. View

5.
Soydan S, Araz K, Senel F, Yurtcu E, Helvacioglu F, Dagdeviren A . Effects of alendronate and pamidronate on apoptosis and cell proliferation in cultured primary human gingival fibroblasts. Hum Exp Toxicol. 2015; 34(11):1073-82. DOI: 10.1177/0960327115569808. View